Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence.

Darici, Salihanur; Alkhaldi, Hazem; Horne, Gillian; Jørgensen, Heather G; Marmiroli, Sandra; Huang, Xu.

Darici S; Haemato-Oncology/Systems Medicine Group, Paul O'Gorman Leukaemia Research Centre, University of Glasgow, Glasgow G12 0ZD, UK.
Alkhaldi H; Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41124 Modena, Italy.
Horne G; Haemato-Oncology/Systems Medicine Group, Paul O'Gorman Leukaemia Research Centre, University of Glasgow, Glasgow G12 0ZD, UK.
Jørgensen HG; Haemato-Oncology/Systems Medicine Group, Paul O'Gorman Leukaemia Research Centre, University of Glasgow, Glasgow G12 0ZD, UK.
Marmiroli S; Haemato-Oncology/Systems Medicine Group, Paul O'Gorman Leukaemia Research Centre, University of Glasgow, Glasgow G12 0ZD, UK.
Huang X; Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, 41124 Modena, Italy.

J Clin Med ; 9(9)2020 Sep 11.

Article en En | MEDLINE | ID: mdl-32932888